Distribution of nerve growth factor following direct delivery to brain interstitium

Several studies suggest the potential of nerve growth factor (NGF) in the treatment of patients with Alzheimer's disease. To characterize NGF transport within the brain interstitium, we implanted controlled release polymers containing NGF and [125I]NGF into the brains of adult male rats and measured spatial distributions of NGF for up to one week. NGF concentration in the brain was quantified using ELISA, radiation counting, and autoradiography. At 2 days post-implantation, quantities of NGF in excess of 50 pg per section were detected within thick (1 mm) coronal slices of the hemisphere ipsilateral to the site of implantation up to 3 mm rostral and caudal to the edge of the polymer. Lower levels of radioactivity (> 5 pg but < 50 pg NGF per section) could be detected throughout the rest of the brain. Levels were highest in the tissue sections containing the polymer, reaching 9.5 ng per section. Autoradiography of thin (20 microns) coronal sections indicated that local NGF concentrations immediately adjacent to the polymer approached 40 micrograms/ml. Analysis of sequential sections on the autoradiograph confirmed that NGF was transported only 2-3 mm from the polymer in any direction. At one week post-implantation, the pattern of NGF distribution was similar to that seen at 2 days, and concentrations remained high near the site of the implant. Comparison of local NGF concentration profiles to simple models of diffusion with first-order elimination suggests that the NGF moved through the tissue by diffusion through the interstitial space with a half-life on the order of 0.5 h. The limited range of NGF transport in brain tissue indicates that: (i) protein drug agents such as NGF will probably need to be delivered almost directly to the site of action for efficacy; and (ii) toxicities associated with delivery of NGF and other protein agents to non-target cells, as often occurs with systemic delivery of drugs, may be reduced by local, interstitial delivery since therapy can be restricted to a small volume of the brain.

[1]  D. Price,et al.  Trophic actions of recombinant human nerve growth factor on cultured rat embryonic CNS cells , 1990, Experimental Neurology.

[2]  M. Barbacid,et al.  The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3 , 1991, Cell.

[3]  U. Bickel,et al.  Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Riopelle,et al.  Distribution of neuronal receptors for nerve growth factor in the rat , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  D. Pfaff,et al.  In situ hybridization detection of trka mRNA in brain: Distribution, colocalization with p75NGFR and up‐regulation by nerve growth factor , 1994, The Journal of comparative neurology.

[6]  J. Lile,et al.  Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). , 1989, Science.

[7]  J. Schwaber,et al.  Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[9]  D. Price,et al.  Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates , 1991, Annals of neurology.

[10]  M. Schwab,et al.  Nerve growth factor increases choline acetyl-transferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons , 1985, Neuroscience.

[11]  D. Mash,et al.  Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease , 1989, Neurobiology of Aging.

[12]  F. Gage,et al.  Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Thoenen,et al.  Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. , 1985, The EMBO journal.

[14]  R. Loy,et al.  Basal forebrain magnocellular neurons stain for nerve growth factor receptor: Correlation with cholinergic cell bodies and effects of axotomy , 1987, Journal of neuroscience research.

[15]  T. Powell,et al.  STUDIES OF THE CONNEXIONS OF THE FORNIX SYSTEM , 1954, Journal of neurology, neurosurgery, and psychiatry.

[16]  J. Coyle,et al.  Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system , 1983, The Journal of comparative neurology.

[17]  C. Patlak,et al.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.

[18]  L. Olson,et al.  Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family , 1990, Neuron.

[19]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[20]  F. Gage,et al.  Potential use of nerve growth factor to treat Alzheimer's disease , 1989, Neurobiology of Aging.

[21]  H. Hatanaka,et al.  Septal cholinergic neurons from postnatal rat can survive in the dissociate culture conditions in the presence of nerve growth factor , 1987, Neuroscience Letters.

[22]  F. Hefti,et al.  Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro , 1988, Journal of neuroscience research.

[23]  G. Gregoriadis.  The Carrier Potential of Liposomes in Biology and Medicine , 1976 .

[24]  H. Yeh,et al.  Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  M. Schwab,et al.  Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat , 1984, Brain Research.

[26]  F. Gage,et al.  Response of septal cholinergic neurons to axotomy , 1987, The Journal of comparative neurology.

[27]  F. Gage,et al.  Morphological response of axotomized septal neurons to nerve growth factor , 1988, The Journal of comparative neurology.

[28]  L. Belluscio,et al.  NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of expression , 1990, Neuron.

[29]  L. Greene.  A quantitative bioassay for nerve growth factor (NGF) activity employing a clonal pheochromocytoma cell line , 1977, Brain Research.

[30]  M. Frotscher,et al.  Fine structure of rat septohippocampal neurons: II. A time course analysis following axotomy , 1992, The Journal of comparative neurology.

[31]  A. Sommer,et al.  Isolation and characterization of ciliary neurotrophic factor from rabbit sciatic nerves. , 1990, The Journal of biological chemistry.

[32]  F. Bloom,et al.  Blood-brain barrier penetration and in vivo activity of an NGF conjugate. , 1993, Science.

[33]  K. Whaley,et al.  Antibody diffusion in human cervical mucus. , 1994, Biophysical journal.

[34]  P. Bartlett,et al.  Receptor‐mediated retrograde transport in CNS neurons after intraventricular administration of NGF and growth factors , 1991, The Journal of comparative neurology.

[35]  R. Langer,et al.  Formulation and delivery of proteins and peptides , 1994 .

[36]  D. Price,et al.  Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat , 1991, Experimental Neurology.

[37]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[38]  F. Gage,et al.  Retrograde cell changes in medial septum and diagonal band following fimbria-fornix transection: Quantitative temporal analysis , 1986, Neuroscience.

[39]  T. Nabeshima,et al.  NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. , 1993, Biochemical and biophysical research communications.

[40]  C. Altar,et al.  Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[41]  W. Pardridge.  Peptide drug delivery to the brain , 1991 .

[42]  W. Saltzman,et al.  Controlled release of nerve growth factor from a polymeric implant , 1990, Brain Research.

[43]  H. Thoenen,et al.  Nerve growth factor (NGF) in the rat CNS: Absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra , 1979, Brain Research.

[44]  Steven A. Johnson,et al.  BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease , 1991, Neuron.

[45]  C. Shute,et al.  Confirmation from choline acetylase analyses of a massive cholinergic innervation to the rat hippocampus , 1967, The Journal of physiology.

[46]  D. Price,et al.  Ciliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Sykes,et al.  Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α, 6α-diphenyl glycoluril (Iodogen) , 1981 .

[48]  Fred H. Gage,et al.  Reinnervation of the partially deafferented hippocampus by compensatory collateral sprouting from spared cholinergic and noradrenergic afferents , 1983, Brain Research.

[49]  M. Fahnestock,et al.  NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. , 1994, Brain research. Molecular brain research.

[50]  M. Schwab,et al.  NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? , 1983, Brain research.

[51]  L. Reichardt,et al.  Expression of the beta-nerve growth factor gene correlates with the density of sympathetic innervation in effector organs. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Ishii,et al.  Insulin-like growth factor II stimulates motor nerve regeneration. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  W. Mark Saltzman,et al.  Controlled growth factor delivery induces differential neurite outgrowth in three-dimensional cell cultures , 1993 .

[54]  M. Barbacid,et al.  The trk proto-oncogene encodes a receptor for nerve growth factor , 1991, Cell.

[55]  M. Sofroniew,et al.  Loss of true blue labelling from the medial septum following transection of the fimbria-fornix: evidence for the death of cholinergic and non-cholinergic neurons , 1990, Brain Research.

[56]  M. Johnston,et al.  Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. , 1986, Brain research.

[57]  F. Hefti,et al.  Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases , 1989, Neurobiology of Aging.

[58]  V. Lee,et al.  Trends and Future Perspectives in Peptide and Protein Drug Delivery , 1995 .

[59]  E. Shooter,et al.  The biology and mechanism of action of nerve growth factor. , 1982, Annual review of biochemistry.

[60]  W. Mark Saltzman,et al.  Drugs released from polymers: diffusion and elimination in brain tissue , 1991 .

[61]  L. Burton,et al.  Activity and Biospecificity of Proteolyzed Forms and Dimeric Combinations of Recombinant Human and Murine Nerve Growth Factor , 1992, Journal of neurochemistry.

[62]  J. Fenstermacher,et al.  Cerebrospinal fluid production rates determined by simultaneous albumin and inulin perfusion. , 1970, Experimental neurology.

[63]  F. Gage,et al.  Basal forebrain cell loss following fimbria/fornix transection , 1990, Brain Research.

[64]  Stanley J. Wiegand,et al.  Neurotrophic factors: from molecule to man , 1994, Trends in Neurosciences.

[65]  F. Gage,et al.  Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor , 1987, Nature.

[66]  F. Hefti,et al.  Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[68]  Yves-Alain Barde,et al.  Trophic factors and neuronal survival , 1989, Neuron.

[69]  P. Aebischer,et al.  NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion , 1990, Experimental Neurology.

[70]  W. Weiner,et al.  Nerve growth factor and Alzheimer's disease , 1986, Annals of neurology.

[71]  N. Bodor,et al.  Direct evidence for brain-specific release of dopamine from a redox delivery system. , 1985, Journal of pharmaceutical sciences.